CB 201

Drug Profile

CB 201

Alternative Names: CB201

Latest Information Update: 20 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gardedam Therapeutics
  • Developer Cantabio Pharmaceuticals
  • Class Proteins
  • Mechanism of Action Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 16 Jun 2016 Cantabio and Neuroscience Research Group agree to co-develop DJ-1 protein-targeting small molecule in USA for Parkinson's disease
  • 25 Jan 2016 Preclinical trials in Alzheimer's disease in USA (unspecified route)
  • 25 Jan 2016 Preclinical trials in Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top